Boston Scientific announced the acquisition of nVision Medical, who developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of...
Marketing in the medical device industry has always felt limited. Companies are usually limited on what they share via social media over regulatory concerns, although this is slowly changing. Slowly. ...
Johnson & Johnson Vision just announced one of the more exciting new contact lens products to hit the market in years. They partnered with Transition Optical, the leading provider of photochromic (smart adaptive) lenses and came up with the ACUVUE OASYS...
<p>AveXis shares jumped over 81% after Novartis entered an agreement to acquire the company in a $8.7 billion deal.</p>...
Intersect ENT announced the commercial availability of their long-awaited SINUVA Sinus Implant yesterday. The SINUVA Sinus Implant provides a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery....
Alkermes fell 20% after they received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral investigational medicine ...
Titan Medical announced an important collaboration with Mimic Technologies this morning, sharing that Mimic has successfully demonstrated the first simulation on Titan's surgeon workstation. ...
One of the more ambitious and interesting early stage medtech companies, Bigfoot Biomedical, announced the final close of their Series B, bringing in $55 million, including an undisclosed investment from Abbott. The total funding to date is more than $90...
The rumors have been discussed for two years that Boston Scientific would acquire NxThera, the developer of Rezum, a minimally invasive therapy that treats BPH (benign prostatic hyperplasia). Today Boston Scientific made it official, acquiring NxThera...
On March 10th, Zoll Medical announced the results from the “Vest Prevention of Early Sudden Death Trial (VEST)" as a Late-Breaking Clinical Trial at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, Florida. At first glance,...